Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Starpharma and Makhteshim Agan in Priostar Agrochemical Collaboration

March 13, 2013

MELBOURNE, Australia and TEL-AVIV, Israel, March 13, 2013 /PRNewswire/ –

Starpharma Holdings Ltd (ASX:SPL; OTCQX: SPHRY) and Makhteshim Agan Group today
announced a collaboration program. This will see Starpharma’s Priostar(R) dendrimer
technology applied to novel crop protection formulations across Makhteshim Agan’s
extensive product portfolio.

Makhteshim Agan is the world’s leading manufacturer and distributor of branded
off-patent crop and non-crop protection products, with 2012 global sales of US$2.83B.
Makhteshim Agan serves farmers in 120 countries and operates in Australia as Farmoz.

The collaboration program leverages Makhteshim Agan’s broad product portfolio and
extensive formulation capabilities alongside Starpharma’s Priostar(R) dendrimer
technology. The program includes the development of new formulations of a number of active
ingredients, including three actives with total market sales for 2011, each exceeding
$400m globally. Other terms of the agreement were not disclosed due to commercial
confidentiality restrictions.

“Through this collaboration Starpharma has the opportunity to further extend the reach
of its dendrimer technology in agrochemicals. This partnership which involves multiple
products in major global markets represents an exciting and valuable commercial
opportunity for our Priostar(R) dendrimers,” said Dr. Jackie Fairley, CEO Starpharma. “We
look forward to working closely with Makhteshim Agan to produce exciting new crop
protection products.”

“Makhteshim Agan strives to offer differentiated solutions to address growers’ needs,
based on innovation, quality and value,” said Sami Shabtai, Head of Innovative Development
at Makhteshim Agan. “We actively seek out exciting technologies that can complement our
in-house capabilities and market understanding to deliver effective and simple crop
protection solutions.”

David Peters, Managing Director of Farmoz added “As Makhteshim Agan’s Australian
subsidiary, Farmoz looks forward to applying Starpharma’s dendrimer technology to
complement our effective and reliable Australian portfolio. Australia is an environment
with unique challenges for agriculture and innovation is an important component in our
strategy for providing the solutions today’s Australian growers need.”

The benefits of Starpharma’s Priostar(R) dendrimers to agrochemical companies and
end-user growers can include:

        - Improved product efficacy;
        - More concentrated formulations to reduce supply chain costs and for greater
          ease of handling;
        - Reduction in solvent loading; and,
        - Improved bioavailability through increased adhesion, to reduce losses due to
          rain run-off, and the need for multiple applications.

In addition to the collaboration with Makhteshim Agan, Starpharma continues to advance
the commercialisation of Priostar(R) for crop protection applications through both its own
internal research program and through valued partnerships with other crop protection
companies.

Makhteshim Agan Industries Ltd. is a leading manufacturer and distributor worldwide of
crop-protection solutions and the largest off-patent player in the industry.

The Company supplies efficient solutions to farmers that assist them in combating
disease and increasing yields. In 2012, the Company’s revenues were over $2.83 billion,
and it is ranked seventh in the world in the overall agro-chemicals industry. The Company
is characterized by its know-how, high-level technological-chemical abilities, expertise
in product registration, and observance of strict standards of environmental protection,
stringent quality control and global marketing and distribution channels.

Makhteshim Agan Group sells its crop protection products in over 120 countries and
together with its strategically located global manufacturing and distribution facilities
delivers simplicity in agriculture around the globe.

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is an ASX 300 company and is a
world leader in the development of dendrimer products for pharmaceutical, life science and
other applications.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic
nanoscale polymer that is highly regular in size and structure and well suited to
pharmaceutical and other uses. Starpharma has three core development programs: VivaGel(R)
portfolio, drug delivery and agrochemicals with the Company developing a number of
products internally and others via commercial partnerships.

In Agrochemicals Starpharma has series of industry partnerships with leading industry
players including Nufarm (ASX:NUF) as well as with internal programs including an enhanced
version of glyphosate (the active ingredient in Roundup(R)).

Starpharma’s lead pharmaceutical product is VivaGel(R) (SPL7013 Gel), a gel-based
formulation of a proprietary dendrimer. VivaGel(R) is under clinical development for the
treatment and prevention of bacterial vaginosis (BV).

Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN)
and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel(R
)-coated condom.

In the wider pharmaceutical fields, Starpharma has both partnered and internal
programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma’s
business, which can be identified by the use of forward-looking terminology such as
“promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”,
“estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could
provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions,
or by express or implied discussions regarding potential filings or marketing approvals,
or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to
be materially different from any future results, performance or achievements expressed or
implied by such statements. There can be no assurance that any existing or future
regulatory filings will satisfy the FDA’s and other health authorities’ requirements
regarding any one or more product candidates nor can there be any assurance that such
product candidates will be approved by any health authorities for sale in any market or
that they will reach any particular level of sales. In particular, management’s
expectations regarding the approval and commercialization of the product candidates could
be affected by, among other things, unexpected clinical trial results, including
additional analysis of existing clinical data, and new clinical data; unexpected
regulatory actions or delays, or government regulation generally; our ability to obtain or
maintain patent or other proprietary intellectual property protection; competition in
general; government, industry, and general public pricing pressures; and additional
factors that involve significant risks and uncertainties about our products, product
candidates, financial results and business prospects. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those described herein as anticipated, believed,
estimated or expected. Starpharma is providing this information as of the date of this
document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments
or otherwise.

        Media:
        Buchan Consulting
        Rebecca Wilson
        Mob: +61-417-382-391
        rwilson@buchanwe.com.au

        Haley Price
        Mob: +61-423-139-163
        hprice@buchanwe.com.au

        Starpharma:
        Dr Jackie Fairley, Chief Executive Officer
        +61-3-8532-2704

        Ben Rogers, Company Secretary
        ben.rogers@starpharma.com

http://www.starpharma.com

        Makhteshim Agan Group:
        Rony Patishi-Chillim
        SVP Global Corporate Communication
        IR@ma-industries.com
        +972-73-232-1941

http://www.ma-industries.com

        Farmoz:
        Adam Phelan
        General Manager - Marketing
        adam.phelan@farmoz.com.au
        Mob: +61-417-498-428

http://www.farmoz.com.au

SOURCE Makhteshim Agan Industries Ltd


Source: PR Newswire